Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) emerged as the highest-selling new drug in India in 2024, generating Rs 58 crore in its first year, according to IQVIA data. The oncology drug’s ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...

From the March/April 2025 issue of Car and Driver. You'd think the sight of a new MG might attract more attention, whether it was spied carving up the winding roads of rural Scotland or whizzing ...

Enhertu is supplied in a single-dose vial containing 100mg of lyophilized powder for reconstitution and further dilution prior to IV infusion. Patients should be selected for treatment with ...